Results 11 to 20 of about 152,710 (293)

Pembrolizumab related Guillain barre syndrome, a rare presentation in a patient with a history of lupus and bladder cancer

Journal of Community Hospital Internal Medicine Perspectives, 2021
Immune checkpoint inhibitor-related neurotoxicity causing Guillain Barre Syndrome is relatively uncommon. We discussed an 80-year-old patient with known systemic lupus erythematosus who presented with lower extremity weakness, areflexia and then ...
Vikram Sangani, Mytri Pokal, Mamtha Balla, Ganesh Prasad Merugu, Sreedhar Adapa, Srikanth Naramala, Venu Madhav Konala   +6 more
doaj   +1 more source

Efficacy and Safety of Immune Checkpoint Inhibitor in Advanced Esophageal Squamous Cell Carcinoma: A Meta-Analysis

Frontiers in Oncology, 2021
BackgroundThe published evidence from several randomized controlled clinical trials of immunotherapy for advanced esophageal squamous cell carcinoma has shown promising results. This study aimed to investigate the efficacy and safety of immune checkpoint
Yi-Min Gu, Qi-Xin Shang, Yue Zhuo, Jian-Feng Zhou, Bo-Wei Liu, Wen-Ping Wang, Guo-Wei Che, Long-Qi Chen   +7 more
doaj   +1 more source

Effectiveness of corticosteroids on immune checkpoint inhibitor-induced interstitial pneumonia among patients with a history of interstitial pneumonia: A case series

SAGE Open Medical Case Reports, 2021
There are few reports on the effectiveness of corticosteroids for immune checkpoint inhibitor-induced interstitial pneumonia in patients with a history of interstitial pneumonia.
Takenori Ichimura, Miwa Hinata, Daisuke Ichikura, Shinya Suzuki   +3 more
doaj   +1 more source

Longitudinal observation of insulin secretory ability before and after the onset of immune checkpoint inhibitor‐induced diabetes mellitus: A report of two cases

Clinical Case Reports, 2021
Immune checkpoint inhibitor‐induced diabetes mellitus is a rare immune‐related adverse event. This report illustrates clinical data and insulin secretory ability before and after the onset of immune checkpoint inhibitor‐induced diabetes.
Noriko Fujiwara, Mayu Watanabe, Akihiro Katayama, Yohei Noda, Jun Eguchi, Hitomi Kataoka, Shunsuke Kagawa, Jun Wada   +7 more
doaj   +1 more source

Adverse effects of immune checkpoint inhibitor therapies on right ventricular function and pulmonary arterial dilatation

Pulmonary Circulation, 2021
Immunologic risk factors contribute to endothelial dysfunction and development of pulmonary vascular disease. Immune checkpoint inhibitors, used as immunotherapies for malignancies, have a wide range of reported immune-related adverse events.
Ruben Mylvaganam, Ryan Avery, Isaac Goldberg, Courtney Makowski, Ravi Kalhan, Victoria Villaflor, Michael J. Cuttica   +6 more
doaj   +1 more source

Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer

Scientific Reports, 2023
Immune checkpoint inhibitors have significantly improved the prognosis in patients with non-small cell lung cancer, compared with cytotoxic agents.
Minehiko Inomata, Masahiro Matsumoto, Naoki Takata, Kana Hayashi, Zenta Seto, Takahiro Hirai, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui, Kazuyuki Tobe   +14 more
doaj   +1 more source

The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition

Experimental Hematology & Oncology, 2020
This letter describes the potential effect of B cell depletion on immune related adverse events associated with immune checkpoint inhibition. B cell depleting agents such as rituximab reduce B cell to plasma cell differentiation and antibody production ...
Rasmus Strøm Risbjerg, Mie Vennize Hansen, Anne Sofie Sørensen, Tue Wenzel Kragstrup   +3 more
doaj   +1 more source

Chronic immune checkpoint inhibitor pneumonitis

Journal for ImmunoTherapy of Cancer, 2020
Background Pneumonitis from immune checkpoint inhibitors (ICI) is a potentially fatal immune-related adverse event (irAE) from antiprogrammed death 1/programmed death ligand 1 immunotherapy. Most cases of ICI pneumonitis improve or resolve with 4–6 weeks
Julie R Brahmer, Patrick M Forde, Evan J Lipson, Jarushka Naidoo, Joanne Riemer, Daphne Wang, Janis M Taube, Cheng Ting Lin, Peter B Illei, Tricia R Cottrell, Lonny B Yarmus, K Ranh Voong, David Feller-Kopman, Hans Lee, Sonye K Danoff, Franco R D'Alessio, Karthik Suresh   +16 more
doaj   +1 more source

Gene signature reveals decreased SOX10-dependent transcripts in malignant cells from immune checkpoint inhibitor-resistant cutaneous melanomas

iScience, 2023
Summary: Evidence is mounting for cross-resistance between immune checkpoint and targeted kinase inhibitor therapies in cutaneous melanoma patients. Since the loss of the transcription factor, SOX10, causes tolerance to MAPK pathway inhibitors, we used ...
Timothy J. Purwin, Signe Caksa, Ahmet Sacan, Claudia Capparelli, Andrew E. Aplin   +4 more
doaj   +1 more source

SnapShot: Immune Checkpoint Inhibitors

Cancer Cell, 2017
Immunotherapy has changed the landscape of cancer treatment. Checkpoint blockade therapies unleash breaks in the immune system and induce long-lasting responses. However, a significant number of patients do not respond (innate resistance), and a subset progress after responding (acquired resistance).
Abril-Rodriguez, Gabriel, Ribas, Antoni
openaire   +4 more sources